Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Question

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 24, 2021 11:42pm

107 Views

Post# 33449074

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Question

Do I understand it correctly that if TH keeps the rights to market TH-1902 themselves they pay significantly less royalties than if the license others to market it? Still, while that incentivizes TH to hold onto as many indications as possible, they almost certainly would still partner on many indications as they likely don't have the capacity to gear up to market all the potential indications (assuming the drug works as we expect).

qwerty22 wrote:
Transfert are named as owner of Katana in the sale contract. If I had to guess then some sort of entity set up to handle the royalty payments on behalf of the actual owners. No matter.

As consultants, employees, shareholders and royalty receivers they are invested in the future of the program in the short, medium and long term. They haven't taken the loot and left the scene.

palinc2000 wrote: Royalty to whom?

scarlet1967 wrote: Yep, but it will be quite low and based on NET sales unless they sublicense the drug.

qwerty22 wrote:
So there is a royalty?

scarlet1967 wrote: "The royalties payable under the Transfert Plus License Agreement vary between 1% and 2.5% on net sales of a product based on the licensed technology. If we enter into a sublicense agreement, we must pay amounts varying between 5% and 15% of the revenues received under such sublicense agreement. The percentage varies based on the timing of the execution of such sublicense agreement."